Serum amyloid A-induced IL-6 production by rheumatoid synoviocytes  by Koga, Tomohiro et al.
FEBS Letters 582 (2008) 579–585Serum amyloid A-induced IL-6 production by rheumatoid synoviocytes
Tomohiro Kogaa, Takafumi Torigoshib, Satoru Motokawab, Taichiro Miyashitaa, Yumi Maedaa,
Minoru Nakamuraa, Atsumasa Komoria, Yoshihiro Aibaa, Takashi Uemuraa,
Hiroshi Yatsuhashia, Hiromi Ishibashia, Katsumi Eguchic, Kiyoshi Migitaa,*
a Clinical Research Center and Department of Rheumatology, NHO Nagasaki Medical Center, Kubara 2-1001-1, Omura 856-8652, Japan
b Department of Orthopedics Surgery, NHO Nagasaki Medical Center, Japan
c First Department of Internal Medicine, Nagasaki University School of Medicine, Sakamoto 1-7-1, Nagasaki 852-8501, Japan
Received 8 November 2007; revised 10 January 2008; accepted 14 January 2008
Available online 1 February 2008
Edited by Beat ImhofAbstract In this study, we investigated the role of serum amy-
loid A protein (SAA) in the production of interleukin-6 (IL-6)
using rheumatoid arthritis ﬁbroblast-like synoviocytes (RA-
FLS). Recombinant SAA stimulation induced the production of
pro-inﬂammatory cytokine, IL-6, from RA-FLS. The signaling
events induced by SAA included the activation of the mitogen-
activated protein kineases, p38 and JNK1/2 and the activation
of nuclear factor-kappa B (NF-jB). Inhibitor studies have shown
SAA-induced IL-6 production to be down-regulated by NF-jB
inhibition and partially inhibited by p38 or JNK inhibitors.
Our ﬁndings demonstrate that SAA is a signiﬁcant inducer of
IL-6, which is critically involved in RA pathogenesis.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Serum amyloid A protein (SAA) is an acute-phase reactant
found predominantly in the plasma high density lipoprotein
fraction. SAA is released to the circulation in response to
pro-inﬂammatory cytokines and the blood concentration of
SAA can be increased by as much as 1000-fold over the basal
level [1]. The liver is a major source of acute-phase SAA and
inﬂammatory cytokines, such as interleukin-6 (IL-6), TNF-a
and IL-Ib, are potent inducers of SAA expression by hepato-
cytes [2]. However, the extra-hepatic expression of SAA has
also been documented [3].
A number of immunomodulatory roles of SAA have been
reported to show cytokine-like properties [4]. SAA has been
demonstrated to be a chemoattractive ligand for the human
N-formyl peptide receptor-like 1 (FPRL1), a transmembrane
G-protein-coupled receptor [5]. In vitro studies have providedAbbreviations: FLS, ﬁbroblast-like synoviocytes; FPRL1, N-formyl
peptide receptor-like 1; IL-6, interleukin-6; MAPKs, mitogen-activated
protein kineases; NF-jB, nuclear factor-kappa B; RA, rheumatoid
arthritis; SAA, serum amyloid A protein
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doi:10.1016/j.febslet.2008.01.022the evidence that SAA can act as a chemoattractant for mono-
cytes, leukocytes and T lymphocytes [6]. Furthermore, it has
been reported that SAA signiﬁcantly stimulates the secretion
of the pro-inﬂammatory cytokines, TNF-a, IL-8 and IL-Ib,
by cultured human neutrophils [7–9]. These ﬁndings indicate
the important regulatory role of SAA in the inﬂammatory
and immune responses.
Rheumatoid arthritis (RA) is a chronic inﬂammatory disease
characterized by synovitis and the destruction of articular
structures [10]. An important feature of RA synovial ﬁbro-
blasts is an increased production of matrix metalloproteinases
(MMPs) which degrade articular matrix components [11]. RA
synovial ﬁbroblasts also produce pro-inﬂammatory cytokines,
which play a pivotal role in RA pathogenesis [12]. Elevated
SAA levels are observed in the sera, synovial ﬂuids and in-
ﬂamed synovium of RA patients [13,14]. OHara et al. also
demonstrated overexpressed SAA and FPRL1, the receptor
for SAA, in inﬂamed rheumatoid synovial tissues [15]. We
and other investigators have previously demonstrated the de
novo synthesis of SAA from RA-FLS in vitro and the
increased production of matrix metalloproteinase from
SAA-stimulated RA-FLS [16,17]. SAA may be involved in
the pathogenesis of RA; however, it remains unclear whether
SAA is involved in the overproduction of pro-inﬂammatory
cytokines of rheumatoid synovium.
The aim of this study was to investigate the ability of SAA to
induce pro-inﬂammatory cytokine production from RA-FLS,
which plays a central role in the RA pathogenesis. Our data
suggest that SAA appears to participate in the IL-6 overpro-
duction that occurs in the RA synovium.2. Materials and methods
2.1. Reagents
Recombinant human SAA was purchased from Peprotech (Rocky
Hills, NJ). Cycloheximide and actinomycin D were purchased from
Sigma (St. Louis, MD). PD98059, SB203580, SP600125 and BAY11-
7082 were obtained from Calbiochem (San Diego, CA).
2.2. Patients
All RA patients fulﬁlled the American College of Rheumatology cri-
teria for RA. Synovial tissue samples were obtained from ﬁve patients
with RA during synovectomy. Synovial ﬁbroblasts were isolated from
the synovial tissues by enzymatic digestion. The isolated synovial ﬁbro-
blasts were used at the third or fourth passages for subsequent exper-
iments. All experiments were performed with the protocol approved by
the ethics committee of Nagasaki Medical Center.blished by Elsevier B.V. All rights reserved.
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Fig. 1. Formyl peptide receptor-like1 (FPRL1) mRNA and protein
expressions in RA-FLS. Total RNA and cellular extracts from SAA-
treated (2–8 h) or untreated RA-FLS were analyzed by RT-PCR (A)
using primers speciﬁc for FPRL1 and anti-FPRL1 Western blot (B).
Three experiments were performed using diﬀerent RA-FLS and a
representative result is shown.
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RA-FLS (5 · 104) were seeded in 24-well plates containing RPMI
plus 10% FCS for 24 h. Following 24 h of incubation in serum-free
RPMI, the cells were stimulated with SAA (0–1 lM) for 24 h. Cell-free
supernatants were collected by centrifugation at 400 · g for 5 min and
assayed for IL-6 with enzyme-linked immunosorbent assay (ELISA)
kits (R&D Systems, Minneapolis, MN) according to the manufac-
turers instructions.
2.4. Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted from RA-FLS using the RNeasy total
RNA isolation protocol (Qiagen, Crauley, UK). cDNA was prepared
with Superscript reverse transcriptase (Invitrogen, Grand Island, NY).
Speciﬁc FPRL1 were designed to generate a 1.1-kb product: sense pri-
mer 5 0-CACCAGGTGCTGCTGGCAAG-3 0and anti-sense primer 5 0-
AATATCCCTGACCCATCCTCA-30. The ampliﬁcation of the IL-6
transcripts was accomplished on a Light Cycler (Roche Diagnostics,
Mannheim, Germany) using speciﬁc primers. The housekeeping gene
fragment of glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used for veriﬁcation of equal loading.
2.5. Analysis of nuclear factor-kappa B (NF-jB) and mitogen-activated
protein kineases (MAPKs) activation
For measurement of FPRL1, IjB-a and MAPKs by a Western blot
analysis, serum-starved RA-FLS seeded in 6-well plates were stimu-
lated with SAA (1 lM) and the cells were washed by ice-cold PBS
and lysed with a lysis buﬀer (1% Nonidet P 40, 50 mM Tris, pH 7.5,
100 mM NaCl, 50 mM NaF, 5 mM EDTA, 20 mM b-glycerophos-
phate, 1.0 mM sodium orthovanadate, 10 lg/mL aprotinin and
10 lg/mL leupeptin) for 20 min at 4 C. Insoluble material was
removed by centrifugation at 15000 · g for 15 min at 4 C. The super-
natant was saved and the protein concentration was determined using
the Bio-Rad protein assay kit (Bio-Rad, Hercules, CA). An identical
amount of protein (50 lg) for each lysate was subjected to 10%
SDS–polyacrylamide gel electrophoresis, and then transferred to a
nitrocellulose membrane. Western blot analysis using the primary anti-
bodies against FPRL1 (Santa Cruz Biotechnology, Santa Cruz, CA),
IjB-a and phospho-speciﬁc or pan anti-MAPKs antibodies (Bio-
source, Camarillo, CA) was performed with an ECL Western blotting
kit (Amersham, Little Chalfont, UK).
NF-jB nuclear translocation in RA-FLS was detected by immuno-
cytochemistry. Cells grown in 8-chamber culture slides (Lab Tech,
Rockville, MD) were incubated with SAA (1 lM) for 30 min and then
washed in PBS. Cells were ﬁxed in 4% paraformaldehyde for 20 min
and blocked in 0.01% H2O2 for 10 min. Incubation with rabbit poly-
clonal anti-NF-jB p65 (1:100, Santa Cruz Biotechnology) was per-
formed for 1 h then with HRP-conjugated anti-Rabbit IgG (Dako
Japan, Kyoto, Japan) for 30 min and ENVISON plus (Dako) was used
for detection. The slides were washed in PBS, then mounted and as-
sessed by microscopy.
2.6. Preparation of nuclear extracts
The cells were washed with cold phosphate buﬀered saline (PBS),
harvested, and pelleted, then resuspended in buﬀer A (10 mM HEPES,
pH 7.9, 10 mM KC1, 0.6% Nonidet P-40, 1 mM EDTA, 1 mM PMSF
and 1 mM DTT) and incubated on ice for 15 min. After centrifugation
at 14000 rpm for 15 min, the supernatant cytoplasmic protein was col-
lected. The remnants were resuspended in buﬀer B (20 mM PMSF and
1 mM DTT) and incubated on ice for 30 min, and stirred discontinu-
ously every 10 min, and then were centrifuged at 14000 rpm for
15 min, and the supernatant nuclear extract was collected. All proteins
were stored at 80 C. The protein concentration was determined by a
Bio-Rad protein assay kit.
2.7. p65 activity detection
The p65 subunit activity was detected using a Trans AM NF-jB
p65 Kit (Active Motif, Cambridge, MA, USA). The kit contained a
96-well plate on which had been immobilized an oligonucleotide con-
taining the NF-jB consensus site (5 0-GGGACTTTCC-3 0). The active
form of NF-jB contained in the nuclear extract speciﬁcally binds to
this oligonucleotide. The primary antibodies used to detect NF-jB rec-
ognize an epitope on p65 that was accessible only when NF-jB was
activated and bound to its target DNA. An HRP-conjugated second-
ary antibody provided a sensitive colorimetric readout that was easilyquantiﬁed by spectrophotometry. The nuclear extracts (1 lg/well) iso-
lated from SAA-treated RA-FLS were analyzed using this kit.3. Results
3.1. FPRL1 gene expression of RA-FLS
In order to determine whether RA-FLS are able to respond
to SAA, mRNA and protein expressions of SAA receptor,
FPRL1, were investigated. As shown in Fig. 1, FPRL1 mRNA
(A) and protein (B) expressions were detected in SAA-stimu-
lated or unstimulated RA-FLS.
3.2. SSA induces secretion of IL-6 by RA-FLS
In order to evaluate whether SSA can induce increased cyto-
kine production, the levels of IL-6 secretion in SAA-stimulated
FLS were determined by ELISA. SAA stimulation induced a
signiﬁcant IL-6 production by FLS in a dose-dependent man-
ner (Fig. 2A). RA-FLS were stimulated with 1 lM SAA, which
is a physiological concentration in rheumatoid synovial ﬂuids
[18], or TNF-a (50 ng/ml) and secreted IL-6 was measured
by ELISA. IL-6 synthesis by 1 lM SAA was higher in compar-
ison to TNF-a-induced IL-6 synthesis in RA-FLS (Fig. 2B).
In order to investigate the mechanism for SAA-induced IL-6
production, we treated RA-FLS with the transcription inhibi-
tor ActD and the protein synthesis inhibitor CHX. The treated
cells were then stimulated with SAA. Both ActD and CHX
inhibited SAA-induced IL-6 production (Fig. 2C). These re-
sults suggest that transcription and de novo protein synthesis
are required for SAA-induced IL-6 production. The potential
eﬀects of contaminating LPS in the SAA preparation were
examined. SAA was incubated with polymyxin B, an ampho-
philic cyclic polycationic peptide that forms a complex with
LSP preventing LPS-induced cytokine production, before it
was applied to RA-FLS. Polymyxin B did not alter SAA-in-
duced IL-6 secretion. Under the same experimental conditions,
polymyxin B inhibited the LPS-induced IL-6 secretion
(Fig. 2C).
We next determined the level of IL-6 mRNA in SAA-stimu-
lated FLS. Reverse transcription of total RNA was followed
by real-time PCR with speciﬁc primers for human IL-6 and
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Fig. 2. SAA stimulates IL-6 protein synthesis in RA-FLS. (A) RA-FLS were stimulated with various concentrations of recombinant SAA (0–5 lM)
as indicated for 24 h under serum-free conditions. IL-6 protein in the conditioned media was determined by ELISA. Data represent the means of four
independent experiments run in triplicate ± S.D. *P < 0.0001 compared to untreated RA-FLS. (B) RA-FLS were stimulated with SAA (1 lM) or
TNF-a (50 ng/ml) and secreted IL-6 was measured by ELISA. Data are means of three diﬀerent RA-FLS run in triplicate ± S.D. *P < 0.001
compared to SAA-stimulated RA-FLS. (C) RA-FLS were pretreated for 1 h with or without actinomycin D (10 lg/ml), cycloheximide (50 lM) or
polymyxin B (2 IU/ml). The cells were stimulated with SAA (1 lM) or lipopolysaccharide (LPS, 50 ng/ml) for 24 h. Secreted IL-6 was measured by
ELISA. Data are means of three diﬀerent RA-FLS run in triplicate ± S.D. *P < 0.0001 compared to SAA-treated RA-FLS.
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Fig. 3. SAA stimulates IL-6 mRNA expression in RA-FLS. RA-FLS
were treated with 1 lM recombinant SAA for various times as
indicated. IL-6 and GAPDH mRNA expression was determined by
real-time PCR method. Data are means of three diﬀerent RA-FLS run
in triplicate ± S.D.
T. Koga et al. / FEBS Letters 582 (2008) 579–585 581the housekeeping gene, GAPDH. As shown in Fig. 3, elevation
of the IL-6 mRNA was observed after 2 h of SAA stimulation.
This SAA-induced IL-6 mRNA expression reached a plateau
after 4 h.
3.3. Role of NF-jB MAPKs and NF-jB in SAA-induced
synthesis of IL-6
In order to understand the signaling mechanism of SAA-in-
duced IL-6 production in RA-FLS, we determined the activa-tion of MAPKs and NF-jB. SAA-induced phosphorylation of
p38 and JNK 1/2 within 10 min of stimulation (Fig. 4A and B).
Because the expression of the gene for IL-6 requires the activa-
tion of NF-jB [19], we also examined whether SAA can acti-
vate this transcription factor in RA-FLS. Because NF-jB
activation is often accompanied by IjB-a degradation, we
examined the cytosolic IjB-a level in SAA-stimulated RA-
FLS. IjB-a started to degrade 10 min after SAA stimulation
(Fig. 5A). As shown in Fig. 5B, nuclear translocation of the
p65 subunit of NF-jB was demonstrated in SAA-stimulated
RA-FLS similar to that in IL-1b-stimulated RA-FLS (positive
control). The above results suggested the involvement of
MAPKs and NF-jB in the SAA-induced synthesis of IL-6 in
RA-FLS. To ascertain this, the cells were pretreated with the
speciﬁc inhibitor SB203580 (p38 kinase), PD98059 (ERK1/2
kinase), SP600125 (JNK kinase) and Bay11-7082 (NF-jB).
As shown in Fig. 6, the inhibition of NF-jB signaling blocked
the SAA-induced IL-6 secretion without aﬀecting cellular via-
bility. SB203580 and SP600125 partially inhibited the SAA-in-
duced IL-6 production. These results indicate the presence of
converging pathways involving NF-jB and MAPK in the
IL-6 production by SAA.
The DNA binding activity of p65, a subunit of NF-jB, was
analyzed by Trans AM NF-jB p65 kit. The DNA binding
activity of p65 was increased by SAA treatment in RA-FLS.
This SAA-induced p65 activity was completely inhibited by
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Fig. 4. Phosphorylation of p38 and JNK in SAA-treated RA-FLS. RA-FLS were stimulated with 1 lM SAA for indicated times. Phosphorylation of
p38 (A) and JNK1/2 (B) were determined by Western blotting using speciﬁc antibodies against pan or phospho-MAPKs. JNK-I or p-JNK-1 indicate
the pan or the phosphorylated protein levels of JNK-1, respectively. The quantitation of each protein band is shown in the lower panel. Optical
density unit was assigned the ratio of the each band against control band (0 min, un-stimulated RA-FLS). Three experiments were performed using
diﬀerent RA-FLS and a representative result is shown.
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SB203580 or SP600125 inhibited SAA-induced p65 activity
to a lesser degree (Fig. 7). These results indicate that these
MAPKs may independently contribute to the SAA-induced
IL-6 production without aﬀecting the NF-jB pathway.4. Discussion
In this study, we investigated the eﬀects of SAA on the pro-
duction of IL-6, which is implicated in RA pathogenesis [20],
using RA-FLS. We observed that SAA induced the concentra-
tion-dependent IL-6 production. Moreover, this eﬀect of SAA
on IL-6 production was associated with the accumulation of
IL-6 speciﬁc mRNA, thus suggesting that SAA-induced IL-6
production at the transcription level. This is associated with
the degradation of IjB-a, NF-jB nuclear translocation and in-
creased DNA binding activity of NF-jB. IL-6 is detectable at
high levels in the sera and synovial ﬂuids of RA patients, and
the levels of IL-6 correlate with RA disease activity [21]. Fur-
thermore, an IL-6 blockage exhibits promising eﬃcacy in thetreatment of RA [22]. These ﬁndings indicate that IL-6 is an
important pro-inﬂammatory cytokine that is critically involved
in the pathogenesis of RA. RA-FLS have been identiﬁed as
signiﬁcant producers of IL-6 by immunocytochemisty, in situ
mRNA hybridization and by a biochemical analysis of pri-
mary cultures of synoviocytes [23,24]. In view of the patho-
physiological role of IL-6 and the recognition that RA-FLS
contribute to the IL-6 production, SAA seems to be implicated
in rheumatoid inﬂammatory processes through stimulating
FLS to produce IL-6. Furthermore, IL-6 is recognized as the
principal inducer of most acute-phase proteins, including
SAA [2]. Therefore, SAA-induced IL-6 production may en-
hance the sustained SAA production in an autocrine-manner
which perpetuates the rheumatoid inﬂammation.
SAA has been recognized as an acute-phase protein, such as
C-reactive protein [25]. However, recent investigations have
suggested that SAA may play a role in the inﬂammatory pro-
cess through its cytokine-like property, rather than as a passive
responder [4]. For example, SAA has been shown to stimulate
the secretion of the pro-inﬂammatory cytokines, TNF-a and
IL-1b, in human neutrophils [8,9]. In RA-FLS, SAA has been
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Fig. 5. SAA-induced NF-jB activation in RA-FLS. (A) RA-FLS were stimulated with 1 lM SAA for various times as indicated. Western blot
analysis was used to detect the cytoplasmic level of IjB-a in RF-FLS. Time-dependent degradation of IjB-a was observed in SAA-treated RA-FLS.
Equal loading of samples was determined by an antibody against b-actin. Three experiments were performed using diﬀerent RA-FLS and a
representative result is shown. (B) SAA-induced nuclear translocation of NF-jB RA-FLS were stimulated with IL-1b (10 ng/ml, positive control) or
SAA (1 lM) for 30 min. Untreated cells were used as negative control. The nuclear translocation of NF-jB was assessed by immunocytochemical
staining. Bar = 50 lm. Three experiments were performed using diﬀerent RA-FLS and a representative result is shown.
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In rheumatoid synovium, the interaction between FLS and
immigrated immune cells establishes a local cytokine network
[26]. However, very little data are currently available regarding
the function of SAA, which is highly expressed in rheumatoid
synovium, in cellular interaction and the cytokine network.
Our data indicate that the interaction between SAA and RA-
FLS was therefore responsible for the enhanced IL-6 produc-
tion. The levels of SAA were elevated in rheumatoid synovial
ﬂuids [18]. We demonstrated that RA-FLS respond to SAA by
producing a pro-inﬂammatory cytokine, IL-6. Interestingly,
IL-6 induces SAA production in rheumatoid synovial cells
[27], thus providing a positive feedback loop between these
molecules in rheumatoid synovium.
NF-jB transcription factor is centrally involved in cytokine
and chemokine-driven inﬂammatory responses, including IL-6
induction [28]. In our study, treatment with BAY-11-7082
blocked SAA-induced IL-6 production, suggesting that the
eﬀects of SAA are mediated through NF-jB. The involvement
of NF-jB in the SAA-mediated pro-inﬂammatory response
was further conﬁrmed by the demonstration that SAA de-graded IjB-a expression and nuclear translocation of p65, a
subunit of NF-jB, in RA-FLS. In addition to NF-jB, our
study indicates the role of MAPK in SAA-mediated IL-6 gene
expression. Indeed, the pharmacological inhibition of p38
MAPK partially suppressed the SAA-induced IL-6 produc-
tion. Cross-talk of the MAPK pathway with the NF-jB path-
way has also been shown in other studies [29]. However, our
data indicated that the SAA-activated DNA binding activity
of NF-jB was not completely inhibited when the JNK or
p38 activities were blocked by SP600125 or SB20358, thus sug-
gesting that these MAPKs may be involved in IL-6 gene induc-
tion by aﬀecting other signaling pathways. Although the
expression of IL-6 in RA-FLS has been shown to be regulated
primarily by NF-jB [30], previous studies have demonstrated
that the pro-inﬂammatory transcription factor, such as AP-1,
may contribute to the activation of the IL-6 gene [31]. These
ﬁndings suggest that SAA triggers a complex signaling net-
work, thus resulting in IL-6 induction in RA-FLS.
In conclusion, we herein demonstrated that SAA is a strong
IL-6 inducer in rheumatoid synovium. Our data provide valu-
able insight into the cellular mechanisms of how SAA partici-
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Fig. 7. DNA binding activity of p65 in SAA-stimulated RA-FLS. RA-
FLS pretreated with various inhibitors were stimulated with SAA and
nuclear extracts were isolated. The DNA binding activity of p65, NF-
jB subunit was detected Trans AM NF-jB p65 kit using nuclear
extracts as described in Section 2. Data are means of two diﬀerent RA-
FLS run in triplicate ± S.D. BAY; NF-jB inhibitor, BAY-11-7082
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**P < 0.01 compared to SAA-treated RA-FLS.
584 T. Koga et al. / FEBS Letters 582 (2008) 579–585pates in the cytokine network in inﬂamed RA synovium, thus
suggesting that the SAA-mediated pro-inﬂammatory processes
could be potential therapeutic targets in RA.
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